Correction: First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies. [PDF]
Mahadevan D +14 more
europepmc +1 more source
RNA-Based Therapeutics in Genetic Neurodevelopmental Disorders: Bridging Molecular Genetics and Precision Medicine. [PDF]
Focșa IO +11 more
europepmc +1 more source
COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in <i>BRAF</i> V600-Mutant Advanced Melanoma. [PDF]
Ribas A +24 more
europepmc +1 more source
Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study. [PDF]
Masuishi T +13 more
europepmc +1 more source
Beyond antibiotics: artificial intelligence-enabled anti-infective ecosystems for next-generation precision therapeutics against antimicrobial resistance. [PDF]
Pattapulavar V +3 more
europepmc +1 more source
Correction to "The Dual Associations of Peripheral Inflammatory Cells With Brain Reorganization in Insular Gliomas With/Without Epilepsy: An Exploratory Analysis". [PDF]
europepmc +1 more source
<i>In Vitro</i> Antimicrobial Activity of Taurolidine Against Isolates Associated with Catheter-Related Bloodstream Infections. [PDF]
Crandon JL +4 more
europepmc +1 more source
Trastuzumab deruxtecan plus pertuzumab in first-line HER2-positive advanced/metastatic breast cancer. [PDF]
Tolaney SM, Loibl S.
europepmc +1 more source

